直肠他克莫司用于难治性溃疡性直肠炎诱导治疗的疗效
20例完成研究后的计划中期分析显示两组差异显著,研究因伦理考虑提前终止;他克莫司组临床应答、临床缓解和黏膜愈合均优于安慰剂组,未发现安全性问题。
要点
- 直肠他克莫司组临床应答8/11(73%)vs 安慰剂组1/10(10%),P=.004。
- 直肠他克莫司组临床缓解5/11(45%)vs 安慰剂组0/10(0%),P=.015。
- 第8周黏膜愈合他克莫司组8/11(73%)vs 安慰剂组1/10(10%),P=.004。
核心结论
- 直肠他克莫司在难治性溃疡性直肠炎诱导临床应答、临床缓解和黏膜愈合方面比安慰剂更有效。
研究设计与样本
- 随机、双盲、安慰剂对照诱导试验,11例接受直肠他克莫司(0.5 mg/mL),10例接受安慰剂,疗程8周。
- 主要终点为采用Mayo Clinic评分评估的临床应答。
主要发现
- 20例完成研究后的计划中期分析显示两组差异高度显著,研究因伦理考虑提前终止,已入组患者允许完成研究。
- 主要终点达标:他克莫司组8/11(73%)vs 安慰剂组1/10(10%),P=.004。
- 临床缓解:他克莫司组5/11(45%)vs 安慰剂组0/10(0%),P=.015。
- 第8周黏膜愈合:他克莫司组8/11(73%)vs 安慰剂组1/10(10%),P=.004。
- 炎症性肠病问卷较基线增加≥16分:他克莫司组5/11(45%)vs 安慰剂组2/10(20%),P=.36。
关键数值与推荐
- 临床应答:他克莫司组8/11(73%)vs 安慰剂组1/10(10%),P=.004。
- 临床缓解:他克莫司组5/11(45%)vs 安慰剂组0/10(0%),P=.015。
- 第8周黏膜愈合:他克莫司组8/11(73%)vs 安慰剂组1/10(10%),P=.004。
- 炎症性肠病问卷增加≥16分:他克莫司组5/11(45%)vs 安慰剂组2/10(20%),P=.36。
- 第8周部分Mayo评分平均值:他克莫司组3.3±1.2 vs 安慰剂组6.7±0.62,P=.01。
临床怎么用
- 原文未据此给出推荐。
局限性
- 20例完成研究后的计划中期分析显示两组差异高度显著,研究因伦理考虑提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Resistant ulcerative proctitis can be extremely difficult to manage. Topically administered tacrolimus, however, may be effective in difficult-to-treat proctitis. This was a randomized, double-blind, placebo-controlled induction trial of rectal tacrolimus in patients with active ulcerative colitis. METHODS: Eleven patients received rectal tacrolimus (0.5 mg/mL), and 10 placebo, for 8 weeks. The primary endpoint was clinical response by using the Mayo Clinic score. RESULTS: A planned interim analysis after 20 patients had completed the study demonstrated highly significant differences between the groups and the study was closed because of ethical considerations with patients already recruited allowed to complete the study. The primary endpoint was met in 8 of 11 patients receiving rectal tacrolimus and 1 of 10 patients receiving placebo (73% vs 10%; P = .004). Of the secondary endpoints, 5 patients with rectal tacrolimus achieved clinical remission compared with none receiving placebo (45% vs 0%; P = .015). Mucosal healing at Week 8 was achieved in 8 patients receiving rectal tacrolimus compared with 1 (73% vs 10%) receiving placebo (P = .004). The Inflammatory Bowel Disease Questionnaire increased ≥16 points over baseline in 5 of the tacrolimus and 2 (45% vs 20%) of the placebo patients (P = .36). Finally, the average partial Mayo score was numerically lower in the tacrolimus-treated group compared with placebo at Week 2 (4.3 ± 0.74 vs 5.8 ± 0.64; P = .15) and Week 4 (3.7 ± 0.96 vs 5.8 ± 0.6; P = .08) but was significantly lower at Week 8 (3.3 ± 1.2 vs 6.7 ± 0.62; P = .01). There were no safety issues identified with rectal tacrolimus use. CONCLUSIONS: Rectal tacrolimus was more effective than placebo for induction of a clinical response, clinical remission, and mucosal healing in resistant ulcerative proctitis (Clinicaltrials.gov registration: NCT01418131).
引用
- Lawrance IC, Baird A, Lightower D, et al. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2017. PMID: 28286194. doi:10.1016/j.cgh.2017.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。